Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05178693 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lutathera and ASTX727 in Neuroendocrine Tumours

Study acronym: LANTana
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 24, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 31, 2025 to Jun 30, 2026 Completion date: Dec 31, 2025 to Feb 28, 2029v7 Show 1 more changeShow less
    • Completion date: Dec 31, 2025 to Feb 28, 2029
  2. Re-verified, no change to tracked fieldsv6
  3. Eligibility criteria revised Collaborator revisedv5 Show 1 more changeShow less
    • Collaborator revised

    See this version in full on ClinicalTrials.gov ↗

  4. Eligibility criteria expanded, about 1 wordv4 See this version in full on ClinicalTrials.gov ↗
  5. Interventions: ASTX727 (Drug) to ASTX727 (Drug), Lutathera (Radiation) Eligibility criteria shortened, about 8 words · Study description expanded, about 94 wordsv3 Show 2 more changesShow less
    • Eligibility criteria shortened, about 8 words
    • Study description expanded, about 94 words

    See this version in full on ClinicalTrials.gov ↗

  6. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jan 10, 2022 to Apr 25, 2022 · Study sites: 0 to 1v2 Show 2 more changesShow less
    • Start date changed from estimate of Jan 10, 2022 to Apr 25, 2022
    • Study sites: 0 to 1
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients entered into the study will receive ASTX727 orally for 5 days, prior to receiving Lutathera treatment on Day 8, to determine whether pre-treatment with ASTX727 results in re-expression of somatostatin receptor-2 in patients with metastatic neuroendocrine tumours. The study will use \[68Ga\]-DOTA-TATE PET to image epigenetic modification of the receptor locus.
Trial Details
NCT Number NCT05178693
Lead Sponsor Imperial College London
Collaborators: Advanced Accelerator Applications
Conditions Neuroendocrine Tumors
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov